Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis

Jessica Marie Louise Fogel, Donald R. Hoover, Jin Sun, Lynne M. Mofenson, Mary Glenn Fowler, Allan W. Taylor, Newton Kumwenda, Taha E Taha, Susan Eshleman

Research output: Contribution to journalArticle

Abstract

Background: In the Post Exposure Prophylaxis of Infants (PEPI)-Malawi trial, infants received up to 14 weeks of extended nevirapine (NVP) or extended NVP with zidovudine (NVP + ZDV) to prevent postnatal HIV transmission. We examined emergence and persistence of NVP resistance in HIV-infected infants who received these regimens prior to HIV diagnosis. Methods: Infant plasma samples collected at 14 weeks of age were tested using the ViroSeq HIV Genotyping System and a sensitive point mutation assay, LigAmp (for K103N and Y181C). Samples collected at 6 and 12 months of age were analyzed using LigAmp. Results: At 14 weeks of age, NVP resistance was detected in samples from 82 (75.9%) of 108 HIV-infected infants. Although the frequency of NVP resistance detected by ViroSeq was lower in the extended NVP + ZDV arm than in the extended NVP arm, the difference was not statistically significant (38/55 = 69.1% vs. 44/53 = 83.0%, P = 0.12). Similar results were obtained using LigAmp. Using LigAmp, the proportion of infants who still had detectable NVP resistance at 6 and 12 months was similar among infants in the two study arms (at 6 months: 17/20 = 85.0% for extended NVP vs. 21/26 = 80.8% for extended NVP + ZDV, P = 1.00; at 12 months: 9/16 = 56.3% for extended NVP vs.10/13 = 76.9% for extended NVP + ZDV, P = 0.43). Conclusion: Infants exposed to extended NVP or extended NVP + ZDV had high rates of NVP resistance at 14 weeks of age, and resistant variants frequently persisted for 6-12 months. Frequency and persistence of NVP resistance did not differ significantly among infants who received extended NVP only vs. extended NVP + ZDV prophylaxis.

Original languageEnglish (US)
Pages (from-to)911-917
Number of pages7
JournalAIDS
Volume25
Issue number7
DOIs
StatePublished - Apr 24 2011

Fingerprint

Nevirapine
Zidovudine
HIV
Post-Exposure Prophylaxis
Malawi

Keywords

  • HIV
  • infants
  • Malawi
  • nevirapine
  • resistance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. / Fogel, Jessica Marie Louise; Hoover, Donald R.; Sun, Jin; Mofenson, Lynne M.; Fowler, Mary Glenn; Taylor, Allan W.; Kumwenda, Newton; Taha, Taha E; Eshleman, Susan.

In: AIDS, Vol. 25, No. 7, 24.04.2011, p. 911-917.

Research output: Contribution to journalArticle

@article{5af7bb85d1fe4f578ed01b2ccc3572fe,
title = "Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis",
abstract = "Background: In the Post Exposure Prophylaxis of Infants (PEPI)-Malawi trial, infants received up to 14 weeks of extended nevirapine (NVP) or extended NVP with zidovudine (NVP + ZDV) to prevent postnatal HIV transmission. We examined emergence and persistence of NVP resistance in HIV-infected infants who received these regimens prior to HIV diagnosis. Methods: Infant plasma samples collected at 14 weeks of age were tested using the ViroSeq HIV Genotyping System and a sensitive point mutation assay, LigAmp (for K103N and Y181C). Samples collected at 6 and 12 months of age were analyzed using LigAmp. Results: At 14 weeks of age, NVP resistance was detected in samples from 82 (75.9{\%}) of 108 HIV-infected infants. Although the frequency of NVP resistance detected by ViroSeq was lower in the extended NVP + ZDV arm than in the extended NVP arm, the difference was not statistically significant (38/55 = 69.1{\%} vs. 44/53 = 83.0{\%}, P = 0.12). Similar results were obtained using LigAmp. Using LigAmp, the proportion of infants who still had detectable NVP resistance at 6 and 12 months was similar among infants in the two study arms (at 6 months: 17/20 = 85.0{\%} for extended NVP vs. 21/26 = 80.8{\%} for extended NVP + ZDV, P = 1.00; at 12 months: 9/16 = 56.3{\%} for extended NVP vs.10/13 = 76.9{\%} for extended NVP + ZDV, P = 0.43). Conclusion: Infants exposed to extended NVP or extended NVP + ZDV had high rates of NVP resistance at 14 weeks of age, and resistant variants frequently persisted for 6-12 months. Frequency and persistence of NVP resistance did not differ significantly among infants who received extended NVP only vs. extended NVP + ZDV prophylaxis.",
keywords = "HIV, infants, Malawi, nevirapine, resistance",
author = "Fogel, {Jessica Marie Louise} and Hoover, {Donald R.} and Jin Sun and Mofenson, {Lynne M.} and Fowler, {Mary Glenn} and Taylor, {Allan W.} and Newton Kumwenda and Taha, {Taha E} and Susan Eshleman",
year = "2011",
month = "4",
day = "24",
doi = "10.1097/QAD.0b013e328344fedc",
language = "English (US)",
volume = "25",
pages = "911--917",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis

AU - Fogel, Jessica Marie Louise

AU - Hoover, Donald R.

AU - Sun, Jin

AU - Mofenson, Lynne M.

AU - Fowler, Mary Glenn

AU - Taylor, Allan W.

AU - Kumwenda, Newton

AU - Taha, Taha E

AU - Eshleman, Susan

PY - 2011/4/24

Y1 - 2011/4/24

N2 - Background: In the Post Exposure Prophylaxis of Infants (PEPI)-Malawi trial, infants received up to 14 weeks of extended nevirapine (NVP) or extended NVP with zidovudine (NVP + ZDV) to prevent postnatal HIV transmission. We examined emergence and persistence of NVP resistance in HIV-infected infants who received these regimens prior to HIV diagnosis. Methods: Infant plasma samples collected at 14 weeks of age were tested using the ViroSeq HIV Genotyping System and a sensitive point mutation assay, LigAmp (for K103N and Y181C). Samples collected at 6 and 12 months of age were analyzed using LigAmp. Results: At 14 weeks of age, NVP resistance was detected in samples from 82 (75.9%) of 108 HIV-infected infants. Although the frequency of NVP resistance detected by ViroSeq was lower in the extended NVP + ZDV arm than in the extended NVP arm, the difference was not statistically significant (38/55 = 69.1% vs. 44/53 = 83.0%, P = 0.12). Similar results were obtained using LigAmp. Using LigAmp, the proportion of infants who still had detectable NVP resistance at 6 and 12 months was similar among infants in the two study arms (at 6 months: 17/20 = 85.0% for extended NVP vs. 21/26 = 80.8% for extended NVP + ZDV, P = 1.00; at 12 months: 9/16 = 56.3% for extended NVP vs.10/13 = 76.9% for extended NVP + ZDV, P = 0.43). Conclusion: Infants exposed to extended NVP or extended NVP + ZDV had high rates of NVP resistance at 14 weeks of age, and resistant variants frequently persisted for 6-12 months. Frequency and persistence of NVP resistance did not differ significantly among infants who received extended NVP only vs. extended NVP + ZDV prophylaxis.

AB - Background: In the Post Exposure Prophylaxis of Infants (PEPI)-Malawi trial, infants received up to 14 weeks of extended nevirapine (NVP) or extended NVP with zidovudine (NVP + ZDV) to prevent postnatal HIV transmission. We examined emergence and persistence of NVP resistance in HIV-infected infants who received these regimens prior to HIV diagnosis. Methods: Infant plasma samples collected at 14 weeks of age were tested using the ViroSeq HIV Genotyping System and a sensitive point mutation assay, LigAmp (for K103N and Y181C). Samples collected at 6 and 12 months of age were analyzed using LigAmp. Results: At 14 weeks of age, NVP resistance was detected in samples from 82 (75.9%) of 108 HIV-infected infants. Although the frequency of NVP resistance detected by ViroSeq was lower in the extended NVP + ZDV arm than in the extended NVP arm, the difference was not statistically significant (38/55 = 69.1% vs. 44/53 = 83.0%, P = 0.12). Similar results were obtained using LigAmp. Using LigAmp, the proportion of infants who still had detectable NVP resistance at 6 and 12 months was similar among infants in the two study arms (at 6 months: 17/20 = 85.0% for extended NVP vs. 21/26 = 80.8% for extended NVP + ZDV, P = 1.00; at 12 months: 9/16 = 56.3% for extended NVP vs.10/13 = 76.9% for extended NVP + ZDV, P = 0.43). Conclusion: Infants exposed to extended NVP or extended NVP + ZDV had high rates of NVP resistance at 14 weeks of age, and resistant variants frequently persisted for 6-12 months. Frequency and persistence of NVP resistance did not differ significantly among infants who received extended NVP only vs. extended NVP + ZDV prophylaxis.

KW - HIV

KW - infants

KW - Malawi

KW - nevirapine

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=79954615488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954615488&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e328344fedc

DO - 10.1097/QAD.0b013e328344fedc

M3 - Article

VL - 25

SP - 911

EP - 917

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 7

ER -